Cancer Research UK Commercial Partnerships
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Our specialist Commercial Partnerships Team advance discoveries to beat cancer by translating promising scientific research into attractive commercial propositions. With exclusive rights to more than £350m of world-class cancer research a year from the Cancer Research UK network and beyond, we are the gateway to much of the high quality oncology research happening in the UK today. We work closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners.
We develop promising ideas into successful cancer therapeutics, software, devices, diagnostics and enabling technologies. We currently have more than 30 partnered agents in pre-clinical and clinical development and five drugs already on the market and benefiting patients: Temodal, Zytiga, Erivedge, Lynparza and Rubraca.
Our Clinical Development Partnerships (CDP) scheme, run by Cancer Research UK’s Centre for Drug Development, works with leading pharmaceutical and biotechnology companies to progress the development of new agents that may otherwise be delayed in development. Since its establishment 10 years ago, the scheme has seen 20 treatments enter the program, with 13 projects currently in active development.